SPONSOR
Peking University Cancer Hospital & Institute
Total Trials
11
Recruiting
11
Phases
Phase 2, Phase 1, Phase 1, Phase 2
Conditions studied: Limited-stage Small Cell Lung Cancer (LS-SCLC)Lung Cancer, Non-Small CellLung InfectionEsophageal Cancer (EsC)Rectal CancerNSCLCRelapsed B-cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin LymphomaNon-Small Cell Lung CancerNon Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute is a clinical research sponsor with 11 registered studies on ClinicalTrials.gov, of which 11 are actively recruiting participants. Research covers conditions including Limited-stage Small Cell Lung Cancer (LS-SCLC), Lung Cancer, Non-Small Cell, Lung Infection, Esophageal Cancer (EsC).
The trial portfolio spans Phase 2, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peking University Cancer Hospital & Institute
How many clinical trials has Peking University Cancer Hospital & Institute sponsored?
ClinicalMetric currently tracks 11 clinical trials sponsored by Peking University Cancer Hospital & Institute, of which 11 are actively recruiting participants. These trials cover conditions including Limited-stage Small Cell Lung Cancer (LS-SCLC), Lung Cancer, Non-Small Cell, Lung Infection. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peking University Cancer Hospital & Institute research focus on?
Peking University Cancer Hospital & Institute clinical trials span Limited-stage Small Cell Lung Cancer (LS-SCLC), Lung Cancer, Non-Small Cell, Lung Infection, Esophageal Cancer (EsC), Rectal Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peking University Cancer Hospital & Institute clinical trial?
To participate in a Peking University Cancer Hospital & Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peking University Cancer Hospital & Institute trials with current recruitment status updated daily.
Clinical Trials by Peking University Cancer Hospital & Institute
NCT06869239
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06648317
Recruiting
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
Lung Cancer, Non-Small Cell
NCT06869213 Phase 2
Recruiting
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
Esophageal Cancer (EsC)
NCT06209099
Recruiting
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
Rectal Cancer
NCT06924710
Recruiting
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
NSCLC
NCT06313957 Phase 1
Recruiting
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed B-cell Non-Hodgkin Lymphoma
NCT05104788 Phase 2
Recruiting
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT07087223 Phase 1, Phase 2
Recruiting
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Non Small Cell Lung Cancer NSCLC
NCT07529002
Recruiting
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
Solid Tumors
NCT05512481 Phase 2
Recruiting
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Melanoma
NCT06548529
Recruiting
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
HER2 Positive or Suspicious Positive Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology